OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit
Rieke Alten, Yoorim An, Dong‐Hyeon Kim, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 6, pp. 477-489
Closed Access | Times Cited: 17
Rieke Alten, Yoorim An, Dong‐Hyeon Kim, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 6, pp. 477-489
Closed Access | Times Cited: 17
Showing 17 citing articles:
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 919-933
Open Access | Times Cited: 12
Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 919-933
Open Access | Times Cited: 12
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
Davide Giuseppe Ribaldone, L Parisio, Angela Variola, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 1, pp. 77-82
Open Access | Times Cited: 11
Davide Giuseppe Ribaldone, L Parisio, Angela Variola, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 1, pp. 77-82
Open Access | Times Cited: 11
Ecogastroenterology: cultivating sustainable clinical excellence in an environmentally conscious landscape
Κassem Sharif, Enrique Rodríguez de Santiago, Paula David, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 6, pp. 550-563
Closed Access | Times Cited: 3
Κassem Sharif, Enrique Rodríguez de Santiago, Paula David, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 6, pp. 550-563
Closed Access | Times Cited: 3
Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial
Stefan Schreiber, Geert R. DʼHaens, Fraser Cummings, et al.
Digestive and Liver Disease (2024) Vol. 56, Iss. 7, pp. 1204-1212
Open Access | Times Cited: 3
Stefan Schreiber, Geert R. DʼHaens, Fraser Cummings, et al.
Digestive and Liver Disease (2024) Vol. 56, Iss. 7, pp. 1204-1212
Open Access | Times Cited: 3
Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
Philip J Smith, Mathurin Fuméry, Rupert W. Leong, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 9, pp. 1143-1156
Open Access | Times Cited: 7
Philip J Smith, Mathurin Fuméry, Rupert W. Leong, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 9, pp. 1143-1156
Open Access | Times Cited: 7
Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?
Karin Cerna, Dana Ďuricová, Martin Lukás, et al.
Crohn s & Colitis 360 (2023) Vol. 5, Iss. 4
Open Access | Times Cited: 7
Karin Cerna, Dana Ďuricová, Martin Lukás, et al.
Crohn s & Colitis 360 (2023) Vol. 5, Iss. 4
Open Access | Times Cited: 7
Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview
Yeo‐Jin Song, Seoung Wan Nam, Chang‐Hee Suh, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 11, pp. 751-768
Closed Access | Times Cited: 6
Yeo‐Jin Song, Seoung Wan Nam, Chang‐Hee Suh, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 11, pp. 751-768
Closed Access | Times Cited: 6
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)
Heinz Wiendl, John Foley, Gilles Defer, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 5, pp. 1385-1401
Open Access | Times Cited: 1
Heinz Wiendl, John Foley, Gilles Defer, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 5, pp. 1385-1401
Open Access | Times Cited: 1
Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies
Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, et al.
Drug Safety (2023) Vol. 46, Iss. 10, pp. 991-1005
Open Access | Times Cited: 3
Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, et al.
Drug Safety (2023) Vol. 46, Iss. 10, pp. 991-1005
Open Access | Times Cited: 3
Monoclonal Antibodies from Space: Improved Crystallization Under Microgravity During Manufacturing in Orbit
Shimon Amselem, Daniel Kogan, Offir Loboda, et al.
Journal of Exploratory Research in Pharmacology (2024) Vol. 9, Iss. 2, pp. 96-105
Open Access
Shimon Amselem, Daniel Kogan, Offir Loboda, et al.
Journal of Exploratory Research in Pharmacology (2024) Vol. 9, Iss. 2, pp. 96-105
Open Access
Biologics in Focus: A Comprehensive Review of Current Biological and Small Molecules Therapies for Crohn’s Disease in the United Arab Emirates (UAE)
Laith Alrubaiy, Louise Christine Pitsillides, T O'Connor, et al.
Gastrointestinal Disorders (2024) Vol. 6, Iss. 3, pp. 644-660
Open Access
Laith Alrubaiy, Louise Christine Pitsillides, T O'Connor, et al.
Gastrointestinal Disorders (2024) Vol. 6, Iss. 3, pp. 644-660
Open Access
Shot heard around the world? Subcutaneous Infliximab (CT-P13) as Maintenance Therapy for Inflammatory Bowel Disease
Catalina Mulanax, Fernando Velayos
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 841-842
Closed Access
Catalina Mulanax, Fernando Velayos
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 841-842
Closed Access
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Bo‐In Lee, Minjee Kim, Eun Ran Kim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Bo‐In Lee, Minjee Kim, Eun Ran Kim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
Xinyue Hu, Xiaowei Tang, Limin Li, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access
Xinyue Hu, Xiaowei Tang, Limin Li, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access
Reply to Zhao et al
Stephen B. Hanauer, Jean‐Frédéric Colombel
Gastroenterology (2024) Vol. 168, Iss. 3, pp. 631-632
Closed Access
Stephen B. Hanauer, Jean‐Frédéric Colombel
Gastroenterology (2024) Vol. 168, Iss. 3, pp. 631-632
Closed Access
Therapeutic potential of infliximab for pruritus in mice model of cholestasis induced by bile duct ligation: Possible involvement of IL-31
Zahra Soltani, Mohammad Elahi, M. Khavandi, et al.
International Immunopharmacology (2023) Vol. 123, pp. 110806-110806
Closed Access
Zahra Soltani, Mohammad Elahi, M. Khavandi, et al.
International Immunopharmacology (2023) Vol. 123, pp. 110806-110806
Closed Access
Opciones terapéuticas disponibles ante la falla al tratamiento anti-TNF en pacientes con Enfermedad Inflamatoria Intestinal
Ignacio Alfaro, Carolina Figueroa, Carolina Pavez Ovalle, et al.
Revista Gastroenterología Latinoamericana (2023) Vol. 34, Iss. 2
Open Access
Ignacio Alfaro, Carolina Figueroa, Carolina Pavez Ovalle, et al.
Revista Gastroenterología Latinoamericana (2023) Vol. 34, Iss. 2
Open Access
